tebipenem is an orally available carbapenem antibiotic. tebipenem is active against a panel of clinical isolates from a variety of bacterial species (mic50s ≤ 0.0039 ~ 8 μg/ml), including methicillin-resistant strains of staphylococcus aureus (s. aureus) and staphylococcus epidermidis (s. epidermidis), as well as penicillin-resistant streptococcus pneumoniae (s. pneumonia). tebipenem also inhibits β-lactamase in a time- and concentration-dependent manner. tebipenem pivoxil, a derivative of tebipenem, has been under development as the first orally available carbapenem antibiotic for the treatment of respiratory and otolaryngological infections caused by drug-resistant s. pneumonia in pediatric patients.1. hazra s, xu h, blanchard js. tebipenem, a new carbapenem antibiotic, is a slow substrate that inhibits the β-lactamase from mycobacterium tuberculosis. biochemistry, 2014, 53(22): 3671-3678.2. fujimoto k, takemoto k, hatano k, et al. novel carbapenem antibiotics for parenteral and oral applications: in vitro and in vivo activities of 2-aryl carbapenems and their pharmacokinetics in laboratory animals. antimicrobial agents and chemotherapy, 2013, 57(2): 697-707.
